Cost-effectiveness of talazoparib for patients with locally advanced or metastasized breast cancer in Germany. Schwarz F, Arefian H, Hartmann M, Runnebaum I, et al. PLoS One 2022;17:e0278460.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Schwarz F, Arefian H, Hartmann M, Runnebaum I, et al. Cost-effectiveness of talazoparib for patients with locally advanced or metastasized breast cancer in Germany. PLoS One 2022;17:e0278460.
PMID: 36454738